Results 41 to 50 of about 21,908,087 (195)
Background Follicular lymphoma is characterized by the t(14;18) translocation resulting in constitutive expression of BCL-2 protein; however approximately 10–15% of follicular lymphomas do not express BCL-2 protein, and a small fraction of these cases ...
Éva Gagyi+9 more
doaj +1 more source
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-
R. Birkinshaw+13 more
semanticscholar +1 more source
The BCL-2-specific inhibitor, ABT-199 (venetoclax) has exhibited remarkable clinical activity in nearly all cases of chronic lymphocytic leukemia. In contrast, responses are usually much less in diffuse large B-cell lymphoma (DLBCL), despite high level ...
Victoria M. Smith+11 more
doaj +1 more source
Silencing Bcl-2 Expression in Epithelial Cancer Cells Using “Smart” Particles
Short interfering RNA (siRNA) targeted against anti-apoptotic Bcl-2 protein proved to knockdown its expression and trigger cancer cell death. We used degradable, pH-sensitive, comb-like [P(EAA-co-BMA)-b-PNASI-g-P(HMA-co-TMAEMA)] polymer to condense anti ...
Yen-Ling Lin+4 more
doaj +1 more source
Targeting the Bcl-2 Family in B Cell Lymphoma
Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma subtypes share a set of underlying traits that promote the development and sustain malignant B cells.
Clare M. Adams+3 more
semanticscholar +1 more source
Objective:B-cell lymphoma 2 (Bcl-2) is an important member of the Bcl-2 family of proteins that regulate the induction of apoptosis. This study aims to investigate whether Bcl-2 small interfering RNA (siRNA) combined with miR-15a oligonucleotides (ODN ...
Li Ding+6 more
doaj +1 more source
Bcl-2 family members play an important role in the development of malignant lymphoma and can induce drug resistance in anticancer treatment. The development of small molecules targeting Bcl-2 family proteins may be a new strategy for the treatment of ...
Yue-li Sun+6 more
semanticscholar +1 more source
BCL-2 as therapeutic target for hematological malignancies
Disruption of the physiologic balance between cell proliferation and cell death is an important step of cancer development. Increased resistance to apoptosis is a key oncogenic mechanism in several hematological malignancies and, in many cases ...
G. Perini+4 more
semanticscholar +1 more source
Subcellular Localization and Dynamics of the Bcl-2 Family of Proteins
Bcl-2 family proteins are recognized as major regulators of the mitochondrial pathway of apoptosis. They control the mitochondrial outer membrane permeabilization (MOMP) by directly localizing to this organelle.
N. Popgeorgiev, Lea Jabbour, G. Gillet
semanticscholar +1 more source
Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks ...
M. García-Aranda+2 more
semanticscholar +1 more source